BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 2015;6:4-14. [PMID: 25553238 DOI: 10.1177/2040622314551934] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Butt AS, Sharif F, Abid S. Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon? World J Hepatol 2018; 10(2): 267-276 [PMID: 29527262 DOI: 10.4254/wjh.v10.i2.267] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
2 Rohde MD, Tracy L, Komatsu TE, El-Kamary SS, Carter W. No Association Between DAA Treatment for HCV Infection and Herpes Zoster Infection in Analysis of Data From 37 Clinical Trials. Clin Gastroenterol Hepatol 2021;19:1670-8. [PMID: 32835844 DOI: 10.1016/j.cgh.2020.08.042] [Reference Citation Analysis]
3 Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion on Drug Metabolism & Toxicology 2016;12:721-31. [DOI: 10.1080/17425255.2016.1183644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
4 Shih YF, Liu CJ. Hepatitis C Virus and Hepatitis B Virus Co-Infection. Viruses 2020;12:E741. [PMID: 32664198 DOI: 10.3390/v12070741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Mühlbacher A, Bethge S. First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment. Value Health 2016;19:776-87. [PMID: 27712705 DOI: 10.1016/j.jval.2016.04.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
6 Ishikawa T, Abe S, Kojima Y, Kojima S, Yoshida T. Discrepant diagnostic results using two genotyping methods in a chronic hepatitis C patient in serogroup 1: Discrepant genotyping HCV results. Hepatol Res 2016;46:354-6. [DOI: 10.1111/hepr.12536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Kaddah MMY, Talaat W, El Demellawy MA. Determination and structural characterization of ravidasvir metabolites by LC coupled to triple quadrupole linear ion trap MS: Application to pharmacokinetics and phase I metabolism in rats. Biomed Chromatogr 2021;35:e5146. [PMID: 33893663 DOI: 10.1002/bmc.5146] [Reference Citation Analysis]
8 Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810 [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
9 Katanoda K, Hori M, Saito E, Shibata A, Ito Y, Minami T, Ikeda S, Suzuki T, Matsuda T. Updated Trends in Cancer in Japan: Incidence in 1985-2015 and Mortality in 1958-2018-A Sign of Decrease in Cancer Incidence. J Epidemiol 2021;31:426-50. [PMID: 33551387 DOI: 10.2188/jea.JE20200416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
10 Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, Han B, McHutchison JG, Subramanian GM, Cooper C, Agarwal K; BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149:1462-70. [PMID: 26248087 DOI: 10.1053/j.gastro.2015.07.043] [Cited by in Crossref: 170] [Cited by in F6Publishing: 151] [Article Influence: 24.3] [Reference Citation Analysis]
11 Paul F, Pellegrini S, Uzé G. IFNA2: The prototypic human alpha interferon. Gene 2015;567:132-7. [PMID: 25982860 DOI: 10.1016/j.gene.2015.04.087] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
12 Liu X, Gao Y, Niu J. Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.66007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Lemmenmeier E, Gaus B, Schmid P, Hoffmann M. A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C. BMC Dermatol 2016;16:5. [PMID: 27230122 DOI: 10.1186/s12895-016-0042-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 El-karaksy HM, Mogahed EA, El-raziky MS, Saleh D, Besheer M, Mubarak S. Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children. Journal of Interferon & Cytokine Research 2016;36:1-8. [DOI: 10.1089/jir.2015.0066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
15 Khatri A, Dutta S, Marbury TC, Preston RA, Rodrigues L Jr, Wang H, Awni W, Menon RM. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment. Clin Pharmacokinet. 2016; Epub ahead of print. [PMID: 27389403 DOI: 10.1007/s40262-016-0429-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
16 Mohamed MF, Minocha M, Trueman S, Feng T, Enejosa J, Fisniku O, Othman AA. Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate. Clin Pharmacol Drug Dev 2021;10:299-306. [PMID: 32648334 DOI: 10.1002/cpdd.844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Medici MC, Galli C, Calderaro A. Hepatitis C virus screening to reveal a better picture of infection. Trends Microbiol 2015;23:324-6. [PMID: 26047087 DOI: 10.1016/j.tim.2015.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
18 Kao JH, Yu ML, Chen CY, Peng CY, Chen MY, Tang H, Chen Q, Wu JJ. Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study. J Gastroenterol Hepatol 2018;33:1507-10. [PMID: 29346834 DOI: 10.1111/jgh.14096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
19 Murira A, Lapierre P, Lamarre A. Evolution of the Humoral Response during HCV Infection: Theories on the Origin of Broadly Neutralizing Antibodies and Implications for Vaccine Design. Adv Immunol 2016;129:55-107. [PMID: 26791858 DOI: 10.1016/bs.ai.2015.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wandtke T, Woźniak J, Kopiński P. Aptamers in diagnostics and treatment of viral infections. Viruses 2015;7:751-80. [PMID: 25690797 DOI: 10.3390/v7020751] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
21 Tadokoro T, Morishita A, Sakamoto T, Fujihara S, Fujita K, Mimura S, Oura K, Nomura T, Tani J, Yoneyama H, Iwama H, Himoto T, Niki T, Hirashima M, Masaki T. Galectin‑9 ameliorates fulminant liver injury. Mol Med Rep 2017;16:36-42. [PMID: 28534962 DOI: 10.3892/mmr.2017.6606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
22 Poordad F, Castro RE, Asatryan A, Aguilar H, Cacoub P, Dieterich D, Marinho RT, Carvalho A, Siddique A, Hu YB, Charafeddine M, Bondin M, Khan N, Cohen DE, Felizarta F. Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials. J Viral Hepat 2020;27:497-504. [PMID: 31954087 DOI: 10.1111/jvh.13261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Katanoda K, Ito Y, Sobue T. International comparison of trends in cancer mortality: Japan has fallen behind in screening-related cancers. Jpn J Clin Oncol 2021;51:1680-6. [PMID: 34467393 DOI: 10.1093/jjco/hyab139] [Reference Citation Analysis]
24 Hamdy M, Kassim SK, Khairy E, Maher M, Mansour KA, Albreedy AM. Ghrelin gene polymorphism as a genetic biomarker for prediction of therapy induced clearance in Egyptian chronic HCV patients. Gene 2018;649:74-9. [PMID: 29374597 DOI: 10.1016/j.gene.2018.01.077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Poonia B, Kottilil S. Newer therapeutics for hepatitis C. Ann Transl Med 2016;4:31. [PMID: 26889484 DOI: 10.3978/j.issn.2305-5839.2015.10.06] [Reference Citation Analysis]
26 He ZX, Chen XW, Zhou ZW, Zhou SF. Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. Drug Metab Rev 2015;47:470-519. [PMID: 26574146 DOI: 10.3109/03602532.2015.1101131] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
27 Vanwalscappel B, Rato S, Perez-Olmeda M, Díez Fuertes F, Casartelli N, Alcami J, Mammano F. Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients. Virology 2017;500:247-58. [PMID: 27855354 DOI: 10.1016/j.virol.2016.10.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Liu CJ, Chen PJ, Chen DS, Tseng TC, Kao JH. Perspectives on dual hepatitis B and C infection in Taiwan. J Formos Med Assoc 2016;115:298-305. [PMID: 26188762 DOI: 10.1016/j.jfma.2015.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]